Celltrion Healthcare has announced a collaboration that will see the Korean biosimilars giant supply anti-TNF products to 180 Life Sciences, a firm that specializes in repurposing off-patent biologics for new indications where there is significant unmet medical need.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?